Literature DB >> 20192270

Structure-activity relationship of (N)-Methanocarba phosphonate analogues of 5'-AMP as cardioprotective agents acting through a cardiac P2X receptor.

T Santhosh Kumar1, Si-Yuan Zhou, Bhalchandra V Joshi, Ramachandran Balasubramanian, Tiehong Yang, Bruce T Liang, Kenneth A Jacobson.   

Abstract

class="Gene">P2X receptor activation protects in class="Chemical">an class="Disease">heart failure models. MRS2339 3, a 2-chloro-AMP derivative containing a (N)-methanocarba (bicyclo[3.1.0]hexane) system, activates this cardioprotective channel. Michaelis-Arbuzov and Wittig reactions provided phosphonate analogues of 3, expected to be stable in vivo due to the C-P bond. After chronic administration via a mini-osmotic pump (Alzet), some analogues significantly increased intact heart contractile function in calsequestrin-overexpressing mice (genetic model of heart failure) compared to vehicle-infused mice (all inactive at the vasodilatory P2Y(1) receptor). Two phosphonates, (1'S,2'R,3'S,4'R,5'S)-4'-(6-amino-2-chloropurin-9-yl)-2',3'-(dihydroxy)-1'-(phosphonomethylene)-bicyclo[3.1.0]hexane, 4 (MRS2775), and its homologue 9 (MRS2935), both 5'-saturated, containing a 2-Cl substitution, improved echocardiography-derived fractional shortening (20.25% and 19.26%, respectively, versus 13.78% in controls), while unsaturated 5'-extended phosphonates, all 2-H analogues, and a CH(3)-phosphonate were inactive. Thus, chronic administration of nucleotidase-resistant phosphonates conferred a beneficial effect, likely via cardiac P2X receptor activation. Thus, we have greatly expanded the range of carbocyclic nucleotide analogues that represent potential candidates for the treatment of heart failure.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20192270      PMCID: PMC2880888          DOI: 10.1021/jm9018542

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

1.  Adenine nucleotide analogues locked in a Northern methanocarba conformation: enhanced stability and potency as P2Y(1) receptor agonists.

Authors:  R Gnana Ravi; Hak Sung Kim; Jörg Servos; Herbert Zimmermann; Kyeong Lee; Savitri Maddileti; José L Boyer; T Kendall Harden; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-05-09       Impact factor: 7.446

2.  A novel contractile phenotype with cardiac transgenic expression of the human P2X4 receptor.

Authors:  B Hu; Q B Mei; X J Yao; E Smith; W H Barry; B T Liang
Journal:  FASEB J       Date:  2001-10-15       Impact factor: 5.191

3.  Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin.

Authors:  B C Knollmann; B E Knollmann-Ritschel; N J Weissman; L R Jones; M Morad
Journal:  J Physiol       Date:  2000-06-01       Impact factor: 5.182

4.  Tissue distribution of P2X4 receptors studied with an ectodomain antibody.

Authors:  Xuenong Bo; Miran Kim; Stefania L Nori; Ralf Schoepfer; Geoffrey Burnstock; R Alan North
Journal:  Cell Tissue Res       Date:  2003-07-04       Impact factor: 5.249

5.  Structure-activity relationships of pyridoxal phosphate derivatives as potent and selective antagonists of P2X1 receptors.

Authors:  Y C Kim; S G Brown; T K Harden; J L Boyer; G Dubyak; B F King; G Burnstock; K A Jacobson
Journal:  J Med Chem       Date:  2001-02-01       Impact factor: 7.446

Review 6.  Pain and purinergic signaling.

Authors:  Makoto Tsuda; Hidetoshi Tozaki-Saitoh; Kazuhide Inoue
Journal:  Brain Res Rev       Date:  2009-11-18

7.  Synthesis and use of novel ether phospholipid enantiomers to probe the molecular basis of the antitumor Effects of alkyllysophospholipids: correlation of differential activation of c-Jun NH(2)-terminal protein kinase with antiproliferative effects in neuronal tumor cells.

Authors:  Pranati Samadder; Robert Bittman; Hoe-Sup Byun; Gilbert Arthur
Journal:  J Med Chem       Date:  2004-05-06       Impact factor: 7.446

8.  Adenine and deazaadenine nucleoside and deoxynucleoside analogues: inhibition of viral replication of sheep MVV (in vitro model for HIV) and bovine BHV-1.

Authors:  Daniela Salvatori; Rosaria Volpini; Silvia Vincenzetti; Alberto Vita; Stefano Costanzi; Catia Lambertucci; Gloria Cristalli; Sauro Vittori
Journal:  Bioorg Med Chem       Date:  2002-09       Impact factor: 3.641

Review 9.  Molecular physiology of P2X receptors.

Authors:  R Alan North
Journal:  Physiol Rev       Date:  2002-10       Impact factor: 37.312

10.  Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation.

Authors:  Bin Xu; Andrew Stephens; Gary Kirschenheuter; Arthur F Greslin; Xiaoquin Cheng; Joe Sennelo; Marco Cattaneo; Maddalena L Zighetti; Aishe Chen; Soon-Ai Kim; Hak Sung Kim; Norbert Bischofberger; Gary Cook; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-12-19       Impact factor: 8.039

View more
  11 in total

1.  Prevention and rescue of cardiac dysfunction by methanocarba adenosine monophosphonate derivatives.

Authors:  Jian-Bing Shen; Kiran S Toti; Saibal Chakraborty; T Santhosh Kumar; Chunxia Cronin; Bruce T Liang; Kenneth A Jacobson
Journal:  Purinergic Signal       Date:  2020-01-27       Impact factor: 3.765

Review 2.  Cardiac purinergic signalling in health and disease.

Authors:  Geoffrey Burnstock; Amir Pelleg
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

3.  Synthesis and P2Y₂ receptor agonist activities of uridine 5'-phosphonate analogues.

Authors:  Sara Van Poecke; Matthew O Barrett; T Santhosh Kumar; Davy Sinnaeve; José C Martins; Kenneth A Jacobson; T Kendall Harden; Serge Van Calenbergh
Journal:  Bioorg Med Chem       Date:  2012-02-15       Impact factor: 3.641

4.  AMP is an adenosine A1 receptor agonist.

Authors:  Joseph E Rittiner; Ilia Korboukh; Emily A Hull-Ryde; Jian Jin; William P Janzen; Stephen V Frye; Mark J Zylka
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

5.  I2-mediated Csp2-P bond formation via tandem cyclization of o-alkynylphenyl isothiocyanates with organophosphorus esters.

Authors:  Yang Liu; Wenjin Wu; Xiaoyan Sang; Yu Xia; Guojian Fang; Wenyan Hao
Journal:  RSC Adv       Date:  2022-06-20       Impact factor: 4.036

6.  5'-Phosphate and 5'-phosphonate ester derivatives of (N)-methanocarba adenosine with in vivo cardioprotective activity.

Authors:  T Santhosh Kumar; Tiehong Yang; Shilpi Mishra; Chunxia Cronin; Saibal Chakraborty; Jian-Bing Shen; Bruce T Liang; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2013-01-22       Impact factor: 7.446

7.  Copper(ii)-catalyzed tandem cyclization for the synthesis of benzo[d][1,3]thiazin-2-yl phosphonates involving C-P and C-S bond formation.

Authors:  Yang Liu; Shijie Yao; Chaoli Wang; Yahui Zhang; Wenyan Hao
Journal:  RSC Adv       Date:  2020-09-01       Impact factor: 3.361

8.  Identification of metabolically stable 5'-phosphate analogs that support single-stranded siRNA activity.

Authors:  Thazha P Prakash; Walt F Lima; Heather M Murray; Wenyu Li; Garth A Kinberger; Alfred E Chappell; Hans Gaus; Punit P Seth; Balkrishen Bhat; Stanley T Crooke; Eric E Swayze
Journal:  Nucleic Acids Res       Date:  2015-03-09       Impact factor: 16.971

Review 9.  Potential Therapeutic Role of Purinergic Receptors in Cardiovascular Disease Mediated by SARS-CoV-2.

Authors:  Fernanda Dos Anjos; Júlia Leão Batista Simões; Charles Elias Assmann; Fabiano Barbosa Carvalho; Margarete Dulce Bagatini
Journal:  J Immunol Res       Date:  2020-12-01       Impact factor: 4.818

10.  SERS/TERS Characterization of New Potential Therapeutics: The Influence of Positional Isomerism, Interface Type, Oxidation State of Copper, and Incubation Time on Adsorption on the Surface of Copper(I) and (II) Oxide Nanoparticles.

Authors:  Edyta Proniewicz; Tomasz K Olszewski
Journal:  J Med Chem       Date:  2022-03-01       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.